Search details
1.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.
Cell
; 162(5): 974-86, 2015 Aug 27.
Article
in English
| MEDLINE | ID: mdl-26317466
2.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Article
in English
| MEDLINE | ID: mdl-38507751
3.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.
Cell
; 169(2): 361, 2017 04 06.
Article
in English
| MEDLINE | ID: mdl-28388418
4.
Cycling cancer persister cells arise from lineages with distinct programs.
Nature
; 596(7873): 576-582, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34381210
5.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.
Cell
; 164(5): 1073, 2016 Feb 25.
Article
in English
| MEDLINE | ID: mdl-27064190
6.
Integrative transcriptomics and cell systems analyses reveal protective pathways controlled by Igfbp-3 in anthracycline-induced cardiotoxicity.
FASEB J
; 37(6): e22977, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37219486
7.
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
Breast Cancer Res
; 25(1): 2, 2023 01 11.
Article
in English
| MEDLINE | ID: mdl-36631725
8.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 382(6): 514-524, 2020 02 06.
Article
in English
| MEDLINE | ID: mdl-31826360
9.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med
; 382(7): 597-609, 2020 02 13.
Article
in English
| MEDLINE | ID: mdl-31825569
10.
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib.
Oncologist
; 27(10): 811-821, 2022 10 01.
Article
in English
| MEDLINE | ID: mdl-35917168
11.
Role for polo-like kinase 4 in mediation of cytokinesis.
Proc Natl Acad Sci U S A
; 116(23): 11309-11318, 2019 06 04.
Article
in English
| MEDLINE | ID: mdl-31097597
12.
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 379(20): 1926-1936, 2018 Nov 15.
Article
in English
| MEDLINE | ID: mdl-30345905
13.
Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Gynecol Oncol
; 160(2): 539-546, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33229045
14.
Frontiers in HER2-positive breast cancer in 2020.
Curr Opin Obstet Gynecol
; 33(1): 48-52, 2021 02 01.
Article
in English
| MEDLINE | ID: mdl-33369581
15.
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Breast Cancer Res
; 22(1): 89, 2020 08 14.
Article
in English
| MEDLINE | ID: mdl-32795346
16.
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
Breast Cancer Res Treat
; 184(1): 23-35, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-32783178
17.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Cancer Res Treat
; 183(2): 419-428, 2020 Sep.
Article
in English
| MEDLINE | ID: mdl-32683565
18.
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Breast J
; 26(3): 368-375, 2020 03.
Article
in English
| MEDLINE | ID: mdl-31448513
19.
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
Lancet Oncol
; 20(3): 361-370, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30709633
20.
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.
Br J Cancer
; 121(4): 318-324, 2019 08.
Article
in English
| MEDLINE | ID: mdl-31303643